WO2008121029A3 - Use of 9-oxoacridine-10-acetic acid and/or salts and/or its esters thereof for the treatment and prophylaxis of malignant tumors of female reproductive system - Google Patents

Use of 9-oxoacridine-10-acetic acid and/or salts and/or its esters thereof for the treatment and prophylaxis of malignant tumors of female reproductive system Download PDF

Info

Publication number
WO2008121029A3
WO2008121029A3 PCT/RU2008/000206 RU2008000206W WO2008121029A3 WO 2008121029 A3 WO2008121029 A3 WO 2008121029A3 RU 2008000206 W RU2008000206 W RU 2008000206W WO 2008121029 A3 WO2008121029 A3 WO 2008121029A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
oxoacridine
prophylaxis
esters
acetic acid
Prior art date
Application number
PCT/RU2008/000206
Other languages
French (fr)
Other versions
WO2008121029A2 (en
Inventor
Kirill Gennedievich Surkov
Original Assignee
Kirill Gennedievich Surkov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirill Gennedievich Surkov filed Critical Kirill Gennedievich Surkov
Publication of WO2008121029A2 publication Critical patent/WO2008121029A2/en
Publication of WO2008121029A3 publication Critical patent/WO2008121029A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the treatment and/or prophylaxis of tumor reccurence in organs of a female reproductive system. According to the invention, a method of combination therapy is provided, the method including the steps of: (a) administering an effective amount of 9-oxoacridine-10-acetic acid and/or pharmaceutically acceptable salts and/or esters thereof to a patient in need thereof, and (b) hormonotherapy aimed at lowering the aromatase enzyme activity. The proposed method is useful in treatment of breast cancer, cancer uteri, ovarian cancer.
PCT/RU2008/000206 2007-03-29 2008-03-31 Use of 9-oxoacridine-10-acetic acid and/or salts and/or its esters thereof for the treatment and prophylaxis of malignant tumors of female reproductive system WO2008121029A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2007111682/14A RU2363466C2 (en) 2007-03-29 2007-03-29 Method and set for treating and preventing malignant tumours of female reproductive system using 9-oxoacridine-10-acetic acid, and/or salt thereof and/or ester thereof
RU2007111682 2007-03-29

Publications (2)

Publication Number Publication Date
WO2008121029A2 WO2008121029A2 (en) 2008-10-09
WO2008121029A3 true WO2008121029A3 (en) 2009-09-24

Family

ID=39808811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2008/000206 WO2008121029A2 (en) 2007-03-29 2008-03-31 Use of 9-oxoacridine-10-acetic acid and/or salts and/or its esters thereof for the treatment and prophylaxis of malignant tumors of female reproductive system

Country Status (2)

Country Link
RU (1) RU2363466C2 (en)
WO (1) WO2008121029A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
RU2017116070A (en) * 2014-11-07 2018-12-07 Липоксен Текнолоджис Лимитед METHOD FOR TREATING PRIMARY HORMONE RESISTANT ENDOMETRIAL AND BREAST CANCER
RU2730530C1 (en) * 2019-10-29 2020-08-24 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" New chemical compound of l-lysine 9-oxoacridinyl-10-acetate, stimulating production of interleukin-24 and tumour necrosis factor - beta

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2126253C1 (en) * 1996-06-06 1999-02-20 Сурков Кирилл Геннадьевич Agent inducing estrogen and progestine receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2126253C1 (en) * 1996-06-06 1999-02-20 Сурков Кирилл Геннадьевич Agent inducing estrogen and progestine receptors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "neovir-pharmacological properties", INTERNET CITATION, 11 May 2005 (2005-05-11), pages 1 - 4, XP002525230, Retrieved from the Internet <URL:http://web.archive.org/web/20050511172858/http://www.pharmsynthez.com /en/info_page_details.php3?info=26&detail=63> [retrieved on 20090424] *
CHERTKOVA AI ET AL: "Effect of interferon inducer Neovir on the sensitivity MDR1(-) and MDR1(+) cells to antitumor drugs", INTERNET CITATION, vol. 5, no. 4, 1 December 2000 (2000-12-01), pages 1 - 2, XP002525229, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/sites/entrez> [retrieved on 20090423] *
DATABASE WPI Week 200022, Derwent World Patents Index; AN 2000-255145, XP002541407 *
SURKOV K G ET AL: "[Neovir, an interferon inductor, modifies expression of steroid hormone receptors in hormone-dependent tissues and restores sensitivity to tamoxifen in patients with inoperable breast cancer]", MEDLINE,, 1 January 1996 (1996-01-01), XP002525233 *
TSYRLINA E V ET AL: "[Effect of neoadjuvant therapy with neovir on the level of steroid hormone receptors in endometrial cancer tissue]", MEDLINE,, 1 January 2001 (2001-01-01), XP002525232 *

Also Published As

Publication number Publication date
RU2007111682A (en) 2008-10-10
WO2008121029A2 (en) 2008-10-09
RU2363466C2 (en) 2009-08-10

Similar Documents

Publication Publication Date Title
WO2014205555A8 (en) Methods and uses for diagnosis and treatment of prostate cancer
WO2011112953A3 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
SG161307A1 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
EP4218760A3 (en) Treatment regimen utilizing neratinib for breast cancer
MX2009011878A (en) Rna antagonist compounds for the modulation of beta-catenin.
MX2009012271A (en) Rna antagonist compounds for the modulation of her3.
NZ598489A (en) Combination therapy for treating proliferative diseases
WO2005087206A3 (en) Cancer therapy comprising a nuclear receptor ligand and a hdac inhibitor
WO2009073050A3 (en) Use of curcumin to block brain tumor formation in vivo
RU2013131241A (en) COMPOSITIONS CONTAINING PI3K INHIBITOR AND MEK INHIBITOR, AND ALSO THEIR APPLICATION FOR TREATMENT OF CANCER
WO2012012305A3 (en) Combination therapy using a ruthenium complex
MX2010004967A (en) Use of cfms inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer.
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
MX2021015447A (en) Methods of treating cancer by targeting cold tumors.
WO2008121029A3 (en) Use of 9-oxoacridine-10-acetic acid and/or salts and/or its esters thereof for the treatment and prophylaxis of malignant tumors of female reproductive system
GB0718878D0 (en) Photodynamic Theraphy and diagnosis
WO2011133826A3 (en) Method for treating pancreatic cancer
WO2008024026A3 (en) Use of 9-oxoacridine-10-acetic acid, its salts and esters for the treatment, prophylaxis or relapse prevention of prostate cancer
WO2007108958A3 (en) Methods of treating cancer using hypofractionated radiation and texaphyrins
SI1596879T1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
WO2012116357A3 (en) Use of agr3 for treating cancer
UA96980C2 (en) Method for reducing the amount of mucosal deterioration, injury, or damage of mucosal tissues
WO2012075210A3 (en) Method for treating refractory cancer
WO2011133479A3 (en) Combination therapy with a proteasome inhibitor and a gallium complex
WO2007103828A3 (en) Fluorocytidine derivatives and cox-2 inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08753906

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08753906

Country of ref document: EP

Kind code of ref document: A2